Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375242 | 1.00 | MAPK1 (0.55) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12581559 | 0.97 | MAPK1 (0.53) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21563247 | 0.90 | MAPT (0.57) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11113569 | 0.89 | MAPK1 (0.53) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11114231 | 0.89 | MAPK1 (0.53) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11115370 | 0.89 | MAPK1 (0.53) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1687312 | 0.89 | ALDH1A1 (0.60) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11112981 | 0.87 | CYP3A4 (0.53) | MAPK1CYP3A4ALDH1A1LMNATSHR | |
| SCHEMBL30576721 | 0.87 | TPSAB1 (0.60) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL919245 | 0.86 | MAPK1 (0.53) | MAPK1CYP3A4ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590273-B2 | Stabilized glycoside hydrolase variants | NOVOZYMES A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| US-20260008808-A1 | Method for Synthesizing Amide and/or Polypeptide Using Unprotected Amino Acid as Ammonia Component | UNIV GUANGZHOU MEDICAL (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12391934-B2 | Stabilized cellulase variants | NOVOZYMES A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3953463-B1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES AS (DK) | 2025-08-06 | — | — | EP | disclosed |
| EP-4574834-A1 | METHOD FOR SYNTHESIZING AMIDE AND/OR POLYPEPTIDE WITH UNPROTECTED AMINO ACID AS AMINE COMPONENT | GUANGZHOU MEDICAL UNIVERSITY (CN) | 2025-06-25 | — | — | EP | disclosed |
| US-20250084346-A1 | ENCAPSULATED SOLID ENZYME PRODUCT | NOVOZYMES A/S (DK) | 2025-03-13 | — | — | US | disclosed |
| US-20250084394-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2025-03-13 | — | — | US | disclosed |
| CN-119371478-A | Method for synthesizing amide and/or polypeptide by taking transient protection amino acid as ammonia component | 广州医科大学 | 2025-01-28 | — | — | CN | disclosed |
| WO-2025015659-A1 | METHOD FOR SYNTHESIZING AMIDE AND/OR POLYPEPTIDE BY TAKING TRANSIENTLY PROTECTED AMINO ACID AS AMMONIA COMPONENT | 广州医科大学 | 2025-01-23 | — | — | WO | disclosed |
| US-12129498-B2 | Stabilized endoglucanase variants | NOVOZYMES A/S (DK) | 2024-10-29 | — | — | US | disclosed |
| CN-108603146-B | Method for cleaning a medical or dental instrument | 诺维信公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20220186151-A1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES A/S (DK) | 2022-06-16 | — | — | US | disclosed |
| EP-3953463-A1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | Novozymes A/S (DK) | 2022-02-16 | — | — | EP | disclosed |
| EP-0321722-B1 | Process for obtaining dipeptides | DEGUSSA (DE) | 1994-02-16 | — | — | EP | disclosed |
| EP-0326240-B1 | 2-Amino acetamide derivatives | FISONS CORP (US) | 1993-10-20 | — | — | EP | disclosed |
| EP-0401253-A1 | 2-AMINO ACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4871872-A | 2-[(2-aminoacetyl)amino]acetamide derivatives | FISONS CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0326240-A1 | 2-Amino acetamide derivatives | FISONS CORPORATION (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006646-A1 | 2-AMINO ACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0321722-A2 | Process for obtaining dipeptides | Degussa Aktiengesellschaft (DE) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008808-A1 | Method for Synthesizing Amide and/or Polypeptide Using Unprotected Amino Acid as Ammonia Component | ANPEP, PTMS, GCG | MAPK1 2427/4885CYP3A4 2447/4885ALDH1A1 4757/4885 |
| US-12590273-B2 | Stabilized glycoside hydrolase variants | IDUA, IDE, TREH | MAPK1 3202/4885CYP3A4 3052/4885ALDH1A1 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.